Setting Up Precision Medicine Workflows Inside an Interconnected Health System
Precision medicine isn't a product you install. It's a set of decisions your organization makes about how genetic data, clinical records, and treatment protocols actually move between departments. When WellSpan iNET started routing pharmacogenomic results into the CPOE flow, I was the one who ended up cleaning up the edge cases. The idea sounded clean on paper. In practice, it meant dealing with FHIR resources that arrived at 3 AM with malformed extension IDs and no way to flag a failed transmission back to the ordering physician. Here's what actually happens when you try to operationalize precision medicine at scale. You start with a lab order — usually pharmacogenomics panels like CYP2D6, CYP2C19, or TPMT testing. The lab returns results in HL7 ORU messages or FHIR QuestionnaireResponse bundles. Those results need to land somewhere a clinician can act on them before the patient comes back for their next visit. That sounds simple until you realize most EHRs don't have a native pathway for turning a genotype into a dose adjustment alert at the point of prescribing. WellSpan iNET functions as the interoperability backbone that connects their multiple hospital campuses, physician practices, and partner labs under a shared data exchange layer. Instead of point-to-point interfaces between every lab and every EHR instance, you route through a central network that standardizes the transport. The actual precision medicine logic still lives in your clinical decision support rules, but the data gets there reliably because the network handles the handshake, the acknowledgment, and the retry logic.
The counter-intuitive part most people miss is that the precision medicine piece itself — the variant calling, the phenotype assignment, the drug-gene interaction lookup — is usually the easy part. The hard part is getting that result into the right clinician's workflow at the right time. I spent six weeks debugging an issue where CPIC guidelines were being evaluated correctly but the alert only fired for inpatient orders, not outpatient. The rule engine treated the two order sets as completely separate contexts. The fix was adding an outbound FHIR observation subscriber that pushed the genotype result to a shared cross-setting queue, which the outpatient CDS rules could then reference.
The Implementation Pipeline
You need a clear path from order to action. Start by mapping which pharmacogenomic or genomic tests your organization actually orders frequently enough to justify the integration effort. If you're running fewer than 200 panels per year, a manual chart review process might be more practical than building an automated pipeline. Once you've identified your high-volume test types, you're looking at three integration touchpoints: the lab information system sending results, the network carrying them, and the EHR consuming them into clinical decision support. On the WellSpan iNET side, the network uses standard messaging — typically HL7 v2 for legacy lab connections and FHIR R4 for newer integrations. You'll define message maps that translate lab output formats into internal observation resources. I'd recommend starting with a small set of high-value gene-drug pairs like CYP2C19 and clopidogrel, or TPMT and thiopurines. Getting those two working end-to-end gives you a proven pattern you can replicate for additional markers. One thing that catches people off guard is the timeline from result availability to clinician awareness. In our setup, a pharmacogenomic result typically flows from the lab to the network within two hours of validation. From there, the CDS rule evaluates against open medication orders within the next thirty minutes. So if a patient has a standing order set, they get flagged before they walk in. If not, the result sits in their record until the next encounter triggers a review. That latency gap is where most precision medicine programs lose their impact.
Get the Full Details
Edge Cases You'll Actually Encounter
I dealt with a case last year where a patient's CYP2D6 result came back as "normal metabolizer" from one lab, but a reflex test ordered six months later showed "intermediate metabolizer" from a different reference lab. The two results existed as separate observations in the network with no canonicalization logic. Prescribers were seeing both values and had no way to know which one to trust. The workaround was writing a deduplication rule that compared result timestamps and flagged the newer value as the current phenotype while retaining the older result for audit purposes. That took about three days of rule authoring and validation against ten patient records. Another issue involves copy-forward behavior. When a genotype result gets pulled into a new encounter summary, some systems duplicate it as a current problem. That creates noise in the problem list and desensitizes clinicians to alerts. Our solution was tagging genotype observations with a permanent "genomic finding" category rather than routing them through the active problem list. Clinicians can still find the data through the dedicated medication safety review panel, but it doesn't clutter the daily workflow.
Where This Approach Breaks Down
Precision medicine integration through an interoperability network like WellSpan iNET does not solve every problem. It will not help if your lab partners are not sending structured result data. If a community lab is still faxing or printing pharmacogenomic reports, the network has nothing to route. You need committed lab partners who can produce machine-readable outputs, ideally in LOINC-coded FHIR observations with accompanying interpretive codes from valuesets like CPIC or DPWG. There's also a staffing reality. Every new gene-drug pair you add requires rule authors who understand both the clinical guideline and the CDS configuration language. You're not just turning on a toggle. Each addition means writing or updating logic, testing it against sample patients, getting pharmacy and medical board sign-off, and deploying through your change management process. A single pharmacogenomic rule update can take two to four weeks from draft to production in a typical health system. If you plan to expand into tumor marker panels or hereditary cancer risk scores, you need a dedicated team, not a side project handled by someone else's IT staff. The network dependency is another constraint. If WellSpan iNET has an outage or a schema change, all your precision medicine data flow stops until it's resolved. We experienced a two-day disruption once when a network upgrade changed the acknowledgment format for ORU messages. Lab results queued up but didn't trigger alerts. Having a fallback — like a daily batch pull from the lab directly — is worth setting up even if you hope you never need it.
Practical Next Steps
If you're evaluating whether to pursue this kind of integration, start by auditing your current test volume and result delivery methods. Identify which results are already coming back electronically and which are still manual. Build a pilot around the easiest data source first. Get one gene-drug pair working cleanly from order to alert before you commit to scaling. Document every exception case you encounter during the pilot. Those exceptions are what will trip you up when you add the next pair, and having a written record saves weeks of reinvestigating the same problem. The infrastructure exists. The standards are in place. What's still hard is the operational discipline of keeping the rules updated as guidelines change and making sure the data quality doesn't degrade across multiple lab sources. Done carefully, precision medicine integration through a network like WellSpan iNET moves you from reactive chart review to proactive clinical guidance. Done poorly, you end up with a dashboard full of unacted-upon results and frustrated providers who've learned to ignore the alerts.
